TerrAscend Posts Solid Q1 Revenue as Market Eyes U.S. Rescheduling

Revenue Performance Meets Expectations

TerrAscend delivered first-quarter revenue in line with analyst forecasts, sustaining its foothold across six U.S. states despite ongoing federal prohibition. The operator's Canadian stock (ISIN: CA88160R1087) traded modestly higher following the earnings release, reflecting cautious optimism in a sector still navigating Schedule I constraints.

Vertically integrated operations span Pennsylvania, New Jersey, Maryland, Michigan, Ohio, and California. Pennsylvania and New Jersey drove most of the growth, where adult-use markets continue to mature.

Rescheduling Uncertainty Weighs on Multiples

Investor focus has shifted from quarterly performance to the DEA's pending final rule on cannabis rescheduling, expected by late 2026. If cannabis moves from Schedule I to Schedule III under the Controlled Substances Act, operators like TerrAscend would gain access to federal tax deductions under IRC Section 280E. That change could add 15-25% to effective margins overnight.

DEA published its Notice of Proposed Rulemaking in December 2024 following a Health and Human Services recommendation. Public comment closed in March 2025. Administrative law judges haven't yet scheduled hearings.

Pennsylvania Remains Core Revenue Driver

Pennsylvania's medical program generated the largest share of TerrAscend's Q1 revenue, with the state's 21 dispensaries anchoring the operator's East Coast footprint. The state legislature has debated adult-use legalization since 2023, but no bill has reached the governor's desk. Medical patient counts topped 450,000 in April 2026, according to the Pennsylvania Department of Health.

Cultivation and processing facilities in Avondale and Hazleton supply the company's own retail network and wholesale partners.

New Jersey Adult-Use Market Stabilizes

New Jersey's adult-use market, which launched in April 2022, has stabilized after two years of rapid dispensary expansion and price compression. Four dispensaries operate under the Apothecarium and Gage brands. Wholesale flower prices in New Jersey fell 22% year-over-year in Q1 2026, pressuring margins for vertically integrated operators.

As of May 2026, the New Jersey Cannabis Regulatory Commission had issued 87 adult-use retail licenses, up from 54 in May 2025.

California Operations Face Margin Pressure

TerrAscend's California dispensaries in San Leandro and San Jose posted flat revenue amid ongoing price deflation in the state's oversupplied market. Wholesale cannabis prices in California declined 18% in the first quarter compared to Q1 2025, according to data from the California Department of Cannabis Control. The state's illicit market continues to undercut licensed operators on price.

California now accounts for roughly 15% of consolidated revenue, down from 22% in 2023.

Balance Sheet and Capital Allocation

TerrAscend ended Q1 2026 with $47 million in cash and $312 million in total debt. That maintains a leverage ratio limiting near-term acquisition capacity. Since 2024, the company has prioritized debt reduction over expansion, refinancing high-cost notes and extending maturities. Management hasn't announced new M&A targets in 2026.

The operator's capital strategy reflects a sector-wide shift toward profitability and deleveraging as access to public equity markets remains constrained by federal prohibition.

What Investors Are Watching Next

The next catalyst for TerrAscend and its MSO peers is the DEA's final rescheduling decision, expected between September and December 2026. If rescheduling proceeds, operators will face a new set of regulatory questions around interstate commerce, FDA oversight, and state-federal licensing conflicts. Until then? Quarterly results remain a secondary signal.

For full background on TerrAscend's financial trajectory and competitive positioning, see the CannIntel topic hub on TerrAscend earnings.